Biotech Trading Around its 50-Day Moving Average - XBI Index +3.95% YTD. Novavax Spikes on Deal with Sanofi

2024 Doubling the Number of Biotech Transactions from 2023. The Index Waits to Respond

What to Think About Commercial Real Estate? How to Know When to Take A Look

Earnings Season Continues with Lots of Beats - But Little Bounce to the Sector

Earnings Season Highlights a Number of Beats but Not Enough to Raise the Index

ONO Pharmaceutical Acquires Deciphera in a Monster Deal - Earnings Season has Begun with Big Beats

Biotech M&A Quiet Heading Into Earnings Season - Intra-Cellular (ITCI) Drug Hits in Clinical Trial and Creates Potential $1B+ Opportunity

Biotech Capital Markets Activity - 130 Biotech Transactions YTD compared to Just 45 Last Year. $22B vs. $6B. Healthy Numbers but the Index Lags

There is (Much) More to AI Markets than NVIDIA - And That Dip Might Mean a Good Time to Buy

Vertex Announces Their Largest Deal Ever While AbbVie's News Around Neuroscience Drug Maker Makes More Waves

Vertex Pharmaceuticals Announces Largest Acquisition Ever - But Biotech Index Dips

April 2024 Riffin' on Real Estate

Risk On for Q1 - But Returns are Broadening Beyond Tech and Indices are at All-Time Highs

Biotech Rise Starts to Come Down as Index Reverts to the Mean - But as Momentum Cools Solid Fundamentals Look Good

Barrons Highlights a Potential Big Change in Bio Investing - What Happens When $100B in Revenue Comes Up for Grabs?

Momentum and Story Stocks Narrowly Drive the Index - When Will Others Participate?

Merck Hits All-Time High; But Momentum Trading Continues to Push Down the Biotech Index

Lots of Action on the Biotech Secondary Market - 8 Transactions, $1.4B

You Need to Understand the Status of the VIX - More Volatility on the Up than the Down